Continuous Versus Intermittent Ward Monitoring
Launched by THE CLEVELAND CLINIC · Jan 22, 2024
Trial Information
Current as of July 30, 2025
Withdrawn
Keywords
ClinConnect Summary
Postoperative cardiovascular mortality remains common,1 and a third occurs during the initial hospitalization. Deterioration occurs over many hours but is usually unrecognized because vital signs are evaluated a 4-6-hour intervals,2 just as they were a half-century ago when patient acuity was much lower. Recognition of even subtle changes in basic vital signs may allow clinicians to detect cardiopulmonary deterioration well before serious adverse events occur. Consequent clinical interventions may in turn prevent complications, or at least moderate their severity. The investigators therefor...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Are admitted to one of the wards equipped with the Masimo Radius VSM solution;
- • 2. Are ≥18 years old;
- • 3. Are designated American Society of Anesthesiologists physical status 1-4;
- • 4. Had major noncardiac surgery lasting at least 1.5 hours;
- • 5. Are expected to remain hospitalized at least two postoperative nights;
- • 6. Had general anesthesia with or without neuraxial anesthesia.
- Exclusion Criteria:
- • 1. Have language, vision, or hearing impairments that may compromise continuous monitoring;
- • 2. Are designated Do Not Resuscitate, hospice, or receiving end of life care;
- • 3. Have previously participated in the study.
About The Cleveland Clinic
The Cleveland Clinic is a renowned nonprofit academic medical center based in Cleveland, Ohio, recognized for its commitment to advancing healthcare through innovative research and clinical excellence. As a leading sponsor of clinical trials, the Cleveland Clinic leverages its multidisciplinary expertise and state-of-the-art facilities to conduct groundbreaking studies aimed at improving patient outcomes across a wide range of medical conditions. With a strong emphasis on patient-centered care, the institution fosters collaboration among researchers, clinicians, and patients to explore new treatments and therapies, contributing significantly to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cleveland, Ohio, United States
Patients applied
Trial Officials
Daniel Sessler, MD
Principal Investigator
The Cleveland Clinic
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported